Santa Barbara, Calif. - Inamed Corporation and its partner Ipsen,a European pharmaceutical company, reported results of a Phase II dosingstudy of their botulinum toxin type A product yesterday at the AAD meeting.
Expert Reflections: Impact of Dermatology Times
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Rituximab May Provide Alternative Treatment Option for Epidermolysis Bullosa Acquisita
The Cutaneous Connection: Enhancing Vitiligo Care With Nanette Silverberg, MD
First Study Reveals Covariate-Adjusted Effects of New Actinic Keratosis Therapies for Face and Scalp
Insights into Bimekizumab 2-Year Data for PsA, nr-asSpA, and AS